Innovative Cellular Analysis LevitasBio’s groundbreaking LeviCell system offers true biology insights without damaging cells, providing a unique value proposition for academic and industrial research labs seeking high-fidelity cellular data.

Recent Technology Launches The recent release of the LeviCell EOS system and associated reagent kits presents sales opportunities to labs focusing on high-throughput cell isolation and enrichment, especially within immunology research sectors.

Strategic Industry Partnerships Collaborations with Cytiva and Planet Innovation showcase LevitasBio’s expanding market reach and validated technology, creating avenues for upselling and deeper integration with key research and biotech clients.

Growing Market Presence With Series C funding of $35 million and revenue between $10 million and $25 million, LevitasBio is scaling operations, opening opportunities for enterprise sales to larger labs and research centers seeking advanced cellular analysis tools.

Competitive Edge LevitasBio’s focus on preserving native cellular signatures positions it as a premium solution compared to traditional methods, making it attractive to cutting-edge research institutions aiming for highly accurate biological data.